Thực trạng sử dụng thuốc sinh học trong điều trị viêm khớp dạng thấp tại Bệnh viện Đại học Y Hà Nội

Abstract

Rheumatoid arthritis (RA) treatment has been revolutionized with the introduction of biological medications. To describe the current state of biologics use at Hanoi Medical University Hospital, a study was conducted on 99 inpatients who met the ACR/EULAR 2010 criteria for RA treated with biological medications from January 2023 to July 2024. Tocilizumab, an inhibitor of interleukin-6, was the most common biological medication selected to treat RA at 57.6%, followed by Golimumab, an anti-TNF-α group member at 24.2%... 56.6% of patients switched biological drugs, with 44.6% of those cases including two or more medications changes. Lack of responsiveness to treatment (46.4%) and insufficient drug supply (39.3%) were the primary causes of drug switching. Drug discontinuation and dose extension rates were 57.6% and 72.7%, respectively. Among the drug discontinuation group, 35.1%, 49.2% and 70.2% of patients stopped biological therapy after 6, 12 and 24 months, respectively. The majority of patients (49.1 and 38.9%, respectively) discontinued the medication or skipped doses because they could not afford to continue their therapy.